Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization

ACS Medicinal Chemistry Letters

Volumn 6, Issue 1, 2015, Pages 89-94

  Okamoto, Kiyoshi ^a   Ikemori Kawada, Megumi ^a   Jestel, Anja ^b   Von König, Konstanze ^b   Funahashi, Yasuhiro ^c   Matsushima, Tomohiro ^a   Tsuruoka, Akihiko ^a   Inoue, Atsushi ^a   Matsui, Junji ^a  

^a EISAI CO LTD   (Japan)

^b PROTEROS BIOSTRUCTURES GMBH   (Germany)

^c EISAI INC   (United States)

Author keywords

kinase inhibitor; kinetic interaction analysis; Receptor tyrosine kinase; VEGFR2; X ray crystallography

Indexed keywords

LENVATINIB; SORAFENIB; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BINDING SITE; BIOCHEMISTRY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG POTENCY; DRUG PROTEIN BINDING; HINGE REGION; HYDROGEN BOND; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; STRUCTURE ANALYSIS; X RAY ANALYSIS;

EID: 84920711920     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500394m     Document Type: Article

References (27)

1. Folkman, J. Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease. Nat. Med. 1995, 1, 27-31.
2. Carmeliet, P.; Jain, R. K. Angiogenesis in Cancer and Other Diseases. Nature 2000, 407, 249-257.
3. Rini, B. I.; Escudier, B.; Tomczak, P.; Kaprin, A.; Szczylik, C.; Hutson, T. E.; Michaelson, M. D.; Gorbunova, V. A.; Gore, M. E.; Rusakov, I. G.; Negrier, S.; Ou, Y.-C.; Castellano, D.; Lim, H. Y.; Uemura, H.; Tarazi, J.; Cella, D.; Chen, C.; Rosbrook, B.; Kim, S.; Motzer, R. J. Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial. Lancet 2011, 378, 1931-1939.
4. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in Advanced Hepatocellular Carcinoma. N. Engl. J. Med. 2008, 359, 378-390.
5. Grothey, A.; Van Cutsem, E.; Sobrero, A.; Siena, S.; Falcone, A.; Ychou, M.; Humblet, Y.; Bouche, O.; Mineur, L.; Barone, C.; Adenis, A.; Tabernero, J.; Yoshino, T.; Lenz, H. J.; Goldberg, R. M.; Sargent, D. J.; Cihon, F.; Cupit, L.; Wagner, A.; Laurent, D. Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet 2013, 381, 303-312.
6. Liu, Y.; Gray, N. S. Rational Design of Inhibitors That Bind to Inactive Kinase Conformations. Nat. Chem. Biol. 2006, 2, 358-364.
7. Tummino, P. J.; Copeland, R. A. Residence Time of Receptor-Ligand Complexes and Its Effect on Biological Function. Biochemistry 2008, 47, 5481-5492.
8. Swinney, D. C. Can Binding Kinetics Translate to a Clinically Differentiated Drug? From Theory to Practice. Lett. Drug Des. Discovery 2006, 3, 569-574.
9. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-Target Residence Time and Its Implications for Lead Optimization. Nat. Rev. Drug Discovery 2006, 5, 730-739.
10. Matsui, J.; Yamamoto, Y.; Funahashi, Y.; Tsuruoka, A.; Watanabe, T.; Wakabayashi, T.; Uenaka, T.; Asada, M. E7080, a Novel Inhibitor That Targets Multiple Kinases, Has Potent Antitumor Activities against Stem Cell Factor Producing Human Small Cell Lung Cancer H146, Based on Angiogenesis Inhibition. Int. J. Cancer 2008, 122, 664-671.
11. Matsui, J.; Funahashi, Y.; Uenaka, T.; Watanabe, T.; Tsuruoka, A.; Asada, M. Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 Via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase. Clin. Cancer Res. 2008, 14, 5459-5465.
12. Okamoto, K.; Kodama, K.; Takase, K.; Sugi, N. H.; Yamamoto, Y.; Iwata, M.; Tsuruoka, A. Antitumor Activities of the Targeted Multi-Tyrosine Kinase Inhibitor Lenvatinib (E7080) against RET Gene Fusion-Driven Tumor Models. Cancer Lett. 2013, 340, 97-103.
13. Schlumberger, M.; Tahara, M.; Wirth, L. J.; Robinson, B.; Brose, M. S.; Elisei, R.; Dutcus, C. E.; de las Heras, B.; Zhu, J.; Habra, M. A.; Newbold, K.; Shah, M. H.; Hoff, A. O.; Gianoukakis, A. G.; Kiyota, N.; Taylor, M. H.; Kim, S.-B.; Krzyzanowska, M. K.; Sherman, S. I. A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial of Lenvatinib (E7080) in Patients with 131I-Refractory Differentiated Thyroid Cancer (SELECT). ASCO Meet. Abstr. 2014, 32, LBA6008.
14. Neumann, L.; Ritscher, A.; Müller, G.; Hafenbradl, D. Fragment-Based Lead Generation: Identification of Seed Fragments by a Highly Efficient Fragment Screening Technology. J. Comput.-Aided Mol. Des. 2009, 23, 501-511.
15. Iwata, H.; Imamura, S.; Hori, A.; Hixon, M. S.; Kimura, H.; Miki, H. Biochemical Characterization of TAK-593, a Novel VEGFR/PDGFR Inhibitor with a Two-Step Slow Binding Mechanism. Biochemistry 2011, 50, 738-751.
16. Iwata, H.; Imamura, S.; Hori, A.; Hixon, M. S.; Kimura, H.; Miki, H. Biochemical Characterization of a Novel Type-II VEGFR2 Kinase Inhibitor: Comparison of Binding to Non-Phosphorylated and Phosphorylated VEGFR2. Bioorg. Med. Chem. 2011, 19, 5342-5351.
17. Traxler, P.; Furet, P. Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors. Pharmacol. Ther. 1999, 82, 195-206.
18. McTigue, M.; Murray, B. W.; Chen, J. H.; Deng, Y. L.; Solowiej, J.; Kania, R. S. Molecular Conformations, Interactions, and Properties Associated with Drug Efficiency and Clinical Performance among VEGFR TK Inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 18281-18289.
19. Copeland, R. A. Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists, 2nd ed.; John Wiley & Sons, Inc.: Hoboken, NJ, 2013; pp 294-299.
20. Schneider, E. V.; Bottcher, J.; Huber, R.; Maskos, K.; Neumann, L. Structure-Kinetic Relationship Study of CDK8/CycC Specific Compounds. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 8081-8086.
21. Liao, J. J. Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors. J. Med. Chem. 2007, 50, 409-424.
22. Nishio, M. CH/Pai Hydrogen Bonds in Crystals. CrystEngComm 2004, 6, 130.
23. Hirabayashi, A.; Mukaiyama, H.; Kobayashi, H.; Shiohara, H.; Nakayama, S.; Ozawa, M.; Miyazawa, K.; Misawa, K.; Ohnota, H.; Isaji, M. Structure-Activity Relationship Studies of 5-Benzylaminoimidazo-[1,2-C]Pyrimidine-8-Carboxamide Derivatives as Potent, Highly Selective ZAP-70 Kinase Inhibitors. Bioorg. Med. Chem. 2009, 17, 284-294.
24. Tohyama, O.; Matsui, J.; Kodama, K.; Hata-Sugi, N.; Kimura, T.; Okamoto, K.; Minoshima, Y.; Iwata, M.; Funahashi, Y. Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models. J. Thyroid Res. 2014, 2014, 638747.
25. Simard, J. R.; Klüter, S.; Grütter, C.; Getlik, M.; Rabiller, M.; Rode, H. B.; Rauh, D. A New Screening Assay for Allosteric Inhibitors of cSrc. Nat. Chem. Biol. 2009, 5, 394-396.
26. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "Gatekeeper Door": Exploiting the Active Kinase Conformation. J. Med. Chem. 2010, 53, 2681-2694.
27. Blanc, J.; Geney, R.; Menet, C. Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design. Anticancer Agents Med. Chem. 2013, 13, 731-747.